leadf
logo-loader
viewFaron Pharmaceuticals Oy
(
AIM:FARNOTC:FPHAF
)

Faron Pharmaceuticals' explains the significance of latest WHO solidarity results

Faron Pharmaceuticals' (LON:FARN) Markku Jalkanen explains the context and meaning behind the latest results from a study that showed little impact from interferon Beta-1a injected under the skin in halting coronavirus-related deaths.

The World Health Organisation's (WHO) Solidarity trial compared 1412 patients who received IFN beta-1a and 2050 control subjects not receiving IFN beta-1a.

The results show that subcutaneous interferon (IFN) beta-1a was found to be safe, but ineffective to reduce overall mortality in hospitalised patients with COVID-19.

Quick facts: Faron Pharmaceuticals Oy

Follow
AIM:FARN

Price: 380 GBX

Market Cap: £191.74 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

Faron Pharmaceuticals presenting at the Proactive One2One Virtual Forum -...

Faron is a clinical stage biopharmaceutical company focused on building the future of immunotherapy by harnessing the power of the immune system in order to tackle cancer and inflammation. Since our founding in 2007, our goal has been to develop a diverse and unique pipeline rooted in high...

5 days, 21 hours ago

2 min read